Compare Cytokinetics Inc (CYTK) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Newegg Commerce Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Newegg Commerce Inc trades at $11.58 (market cap $243.30M). The key difference: Cytokinetics Inc is far larger — about 35.4× Newegg Commerce Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Newegg Commerce Inc for 14 Days on average.
| CYTK | NEGG | |
|---|---|---|
Market Cap | $8.62B | $243.30M |
Volume | 2,594,626 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $92.74 |
52-Week Low | $54.76 | $11.49 |
Typical Hold Time | 19 Days | 14 Days |
Enterprise Value | $8.72B | $213.53M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
NEGG trades at $11.58, down 3.58% on the day, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.11 versus a -$0.40 estimate. The company shows improving fundamentals, with revenue stabilizing around $1.4B and net losses narrowing significantly in 2025. New partnerships with Western Digital and Hewlett Packard Enterprise highlight strategic moves in IT infrastructure.
The outlook is mixed; improving profitability and low P/S ratio offer value, but negative operating cash flow and insider selling pose risks. Analyst consensus is a Buy with a $7.75 target, below the current price, indicating caution. Key risks include competitive pressures and reliance on financing activities for liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
